Research Paper Volume 14, Issue 12 pp 5233—5249

Identification of m7G-associated lncRNA prognostic signature for predicting the immune status in cutaneous melanoma

Jielin Rong1, , Hui Wang2, , Yi Yao1, , Zhengyuan Wu1, , Leilei Chen1, , Chaojie Jin1, , Zhaoyang Shi1, , Cheng Wu1, , Xueqing Hu2, ,

  • 1 Department of Hand Plastic Surgery, The First People's Hospital of Linping District, Hangzhou 311199, China
  • 2 Department of Plastic Surgery, The Second Affiliated Hospital of Zhejiang University, Hangzhou 311199, China

Received: April 11, 2022       Accepted: June 14, 2022       Published: June 29, 2022
How to Cite

Copyright: © 2022 Rong et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


RNA modifications, including RNA methylation, are widely existed in cutaneous melanoma (CM). Among epigenetic modifications, N7-methylguanosine (m7G) is a kind of modification at 5’ cap of RNA which participate in maintaining the stability of mRNA and various cell biological processes. However, there is still no study concerning the relationship between CM and m7G methylation complexes, METTL1 and WDR4. Here, long non-coding RNA (lncRNAs) and gene expression data of CM from the Cancer Genome Atlas (TCGA) database were retrieved to identify differentially expressed m7G-related lncRNAs connected with overall survival of CM. Then, Cox regression analyses was applied to construct a lncRNA risk signature, the prognostic value of identified signature was further evaluated. As a result, 6 m7G-associated lncRNAs that were significantly related to CM prognosis were incorporated into our prognostic signature. The functional analyses indicated that the prognostic model was correlated with patient survival, cancer metastasis, and growth. Meanwhile, its diagnostic accuracy was better than conventional clinicopathological characteristics. The pathway enrichment analysis showed that the risk model was enriched in several immunity-associated pathways. Moreover, the signature model was significantly connected with the immune subtypes, infiltration of immune cells, immune microenvironment, as well as several m6A-related genes and tumor stem cells. Finally, a nomogram based on the calculated risk score was established. Overall, a risk signature based on 6 m7G-associated lncRNAs was generated which presented predictive value for the prognosis of CM patients and can be further used in the development of novel therapeutic strategies for CM.


CM: cutaneous melanoma; m7G: N7-methylguanosine; lncRNAs: long non-coding RNA; TCGA: The Cancer Genome Atlas; GTEx: Genotype-Tissue Expression; OS: overall survival; m1A: N1-methyladenosine; m6A: N6-methyladenosine; CSCs: cancer stem cell-like cells; FDR: false discovery rate; GSEA: Gene Set Enrichment Analysis; KEGG: Kyoto Encyclopedia of Genes and Genomes; ssGSEA: single-sample gene set enrichment analysis.